Compare FTEL & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTEL | OGEN |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.6M |
| IPO Year | 2023 | N/A |
| Metric | FTEL | OGEN |
|---|---|---|
| Price | $3.07 | $0.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 425.2K | ★ 897.5K |
| Earning Date | 11-17-2025 | 03-13-2026 |
| Dividend Yield | ★ 45.45% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,200,138.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.42 | N/A |
| 52 Week Low | $2.91 | $0.74 |
| 52 Week High | $1,427.20 | $18.90 |
| Indicator | FTEL | OGEN |
|---|---|---|
| Relative Strength Index (RSI) | 62.64 | 40.70 |
| Support Level | $2.96 | $0.88 |
| Resistance Level | $3.85 | $1.03 |
| Average True Range (ATR) | 0.32 | 0.06 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 76.48 | 13.64 |
Fitell Corp conducts its primary operations of selling gym and fitness equipment in Australia through its indirectly held wholly owned subsidiary, serving personal training studios and commercial gyms. Its product coverage includes four proprietary brands: Muscle Motion for strength-training equipment, Rapid Motion with a focus on commercial items, FleetX for cardio equipment, and Harison for cardio, strength, recovery, and conditioning products. The Company operates in one segment, trading gym equipment, and also provides licensing services and gym equipment to overseas gym studios. Majority of its business is conducted in Australia via its e-commerce platform and third-party sites, with maximum revenue earned from retail.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.